Eighty-five consecutive patients with relapsed or refractory Hodgkin's disease (HD) underwent high-dose chemotherapy or chemo/radiotherapy followed by autologous bone marrow (ABMT) and/or peripheral blood stem cell (PBSC) transplantation. Two preparative regimens were used. Twenty-two patients (26%) without prior radiation received fractionated total body irradiation (FTBI) 1,200 Gy in combination with high-dose etoposide (VP-16) 60 mg/kg and cyclophosphamide (CTX) 100 mg/kg. Sixty-three patients (74%) with prior radiotherapy received carmustine (BCNU) 450 mg/m2 instead of FTBI. The median age was 32 years (range, 16 to 56). The median number of prior chemotherapy regimens was three (range, 1 t o 7). Forty-three patients (51%) received transplants in first relapse or second complete remission (CR), whereas 33 (39%) received transplants after second or subsequent relapse. All relapsed patients, except one, received conventional salvage chemotherapy and/or radiotherapy in an attempt t o reduce tumor bulk before transplant. At the time of analysis in April 1994, fiftyseven patients (67%) are alive, including 44 (52%) in continuous CR. with a median follow-up for the surviving patients of 28 months (range, 7 t o 66). Thirty patients (35%) relapsed at a median of 9 months (range, 1 t o 43). Eleven patients PPROXIMATELY 60% to 70% of patients with advanced Hodgkin's disease (HD) can be cured with combination chemotherapy.'" However, patients who relapse after attaining a complete remission (CR) with chemotherapy or who fail to respond to induction chemotherapy and have primary refractory disease are rarely cured with conventional salvage chemotherapy or salvage radiotherapy!5 Long-term disease-free survival (DFS) of 5% to 20% has been reported for these patients. Recent studies from the National Cancer Institute (NCI) showed that patients who relapsed more than 12 months after initial remission had a high complete response rate of 85%, compared with 29% for those patients with initial remission of less than 12 months duration! Despite this, the overall survival (OS) of patients with long initial remission is projected to be 24%, and only 1 1 % of patients with short initial remission survive longer than 10 years. High-dose therapy followed by autologous bone m m w transplantation (ABMT) has been shown to produce long-term DFS in selected patients with advanced refractory Approximately 30% to 6 4 % long-term DFS has been reported from several series. Most of these studies have used a high-dose combination chemotherapy regimen, as the majority of patients with relapsed HD have received prior radiotherapy. The most commonly used combinations are: cyclophosphamide, carmustine (BCNU) and etoposide (VP-16) (CBV)6,8 or BCNU, etoposide, cytarabine and melphalan (BEAM).I3 Recently, excellent results were reported with the addition of cisplatin to a modified CBV regimen.'7 In some studies, total body irradiation in combination with high-dose cyclophosphamide was used in a small number (13%) died of transplant-related complications including veno-occlusive disease of the liver (VOD) in five, acute and late interstitial pneumonitis in three, graft failure in one, cerebral hemorrhage in one, and therapy-induced myelodysplasia (MDS)/acute leukemia in one patient. At a median follow-up of 25 months (range, 0.6 t o 66). the cumulative probability of 2-year overall and disease-free survival (DFS) of all 85 patients is 75% (95% confidence interval IC11 64% t o 84%) and 58% (95% Cl 47% t o 69%). respectively. Three independent prognostic variables were identified by univariate analysis: number of prior chemotherapy regimens, prior radiotherapy, and extranodal disease at ABMT. Multivariate stepwise Cox regression identified the number of prior chemotherapy regimens as the only significant prognostic factor predicting for both relapse and DFS. There were no significant differences in the outcome of the treatment between the two preparative regimens. Our results confirm that highdose therapy and ABMT is an effective therapy for patients with relapsed or refractory HD. Earlier transplantation is recommended before the development of drug resistance and end organ damage that results from repeated attempts of salvage therapy. of patients, especially those who had not received previous radiotherapy.'0,'8.19 Hyperfractionated total-lymphoid irradiation in combination with high-dose etoposide and cyclophosphamide has been shown to be efficacious in previously unirradiated patients with relapsing or chemotherapy-resistant HD.I5 At present, there is no evidence to suggest the superiority of one regimen over the other.
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Hodgkin's disease (HD) can be cured with combination chemotherapy.'" However, patients who relapse after attaining a complete remission (CR) with chemotherapy or who fail to respond to induction chemotherapy and have primary refractory disease are rarely cured with conventional salvage chemotherapy or salvage radiotherapy!5 Long-term disease-free survival (DFS) of 5% to 20% has been reported for these patients. Recent studies from the National Cancer Institute (NCI) showed that patients who relapsed more than 12 months after initial remission had a high complete response rate of 85%, compared with 29% for those patients with initial remission of less than 12 months duration! Despite this, the overall survival (OS) of patients with long initial remission is projected to be 24%, and only 1 1 % of patients with short initial remission survive longer than 10 years.
High-dose therapy followed by autologous bone m m w transplantation (ABMT) has been shown to produce long-term DFS in selected patients with advanced refractory Approximately 30% to 6 4 % long-term DFS has been reported from several series. Most of these studies have used a high-dose combination chemotherapy regimen, as the majority of patients with relapsed HD have received prior radiotherapy. The most commonly used combinations are: cyclophosphamide, carmustine (BCNU) and etoposide (VP-16) (CBV)6,8 or BCNU, etoposide, cytarabine and melphalan (BEAM).I3 Recently, excellent results were reported with the addition of cisplatin to a modified CBV regimen. '7 In some studies, total body irradiation in combination with high-dose cyclophosphamide was used in a small number (13%) died of transplant-related complications including veno-occlusive disease of the liver (VOD) in five, acute and late interstitial pneumonitis in three, graft failure in one, cerebral hemorrhage in one, and therapy-induced myelodysplasia (MDS)/acute leukemia in one patient. At a median follow-up of 25 months (range, 0.6 t o 66). the cumulative probability of 2-year overall and disease-free survival (DFS) of all 85 patients is 75% (95% confidence interval IC11 64% t o 84%) and 58% (95% Cl 47% t o 69%). respectively. Three independent prognostic variables were identified by univariate analysis: number of prior chemotherapy regimens, prior radiotherapy, and extranodal disease at ABMT. Multivariate stepwise Cox regression identified the number of prior chemotherapy regimens as the only significant prognostic factor predicting for both relapse and DFS. There were no significant differences in the outcome of the treatment between the two preparative regimens. Our results confirm that highdose therapy and ABMT is an effective therapy for patients with relapsed or refractory HD. Earlier transplantation is recommended before the development of drug resistance and end organ damage that results from repeated attempts of salvage therapy. of patients, especially those who had not received previous radiotherapy.'0,'8.19 Hyperfractionated total-lymphoid irradiation in combination with high-dose etoposide and cyclophosphamide has been shown to be efficacious in previously unirradiated patients with relapsing or chemotherapy-resistant HD.I5 At present, there is no evidence to suggest the superiority of one regimen over the other.
Based on our previous experience of the effective combination of fractionated total body irradiation (FTBI) and highdose W-16 in patients with relapsed acute leukemia," we developed a new conditioning regimen by adding highdose cyclophosphamide to the F T B I and W -l 6 combination. This regimen was used in patients with relapsed lymphoma who had not received prior radiotherapy. Because of the increase in pulmo-
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NADEMANEE ET AL n a q toxicity observed in patients with prior mediastinal radiation receiving a total body irradiation (TBI) containing regimen in our phase 1-11 study and the experiences reported from other investigators," a non-FTBI containing regimen was used in patients who had received prior radiotherapy. We have adopted the CBV regimen but modified it by increasing the doses of BCNU and VP-16. We report here the results of high-dose therapy using these two combinations in patients with advanced HD and have analyzed factors that may affect the outcome.
MATERIALS AND METHODS
Between April 1988 and June 1993, 85 patients with relapsed or refractory HD underwent high-dose therapy and ABMT or peripheral blood stem cell (PBSC) transplantation at City of Hope National Medical Center. The diagnosis and histologic subtype of HD was based on biopsy results at the time of diagnosis in patients with primary refractory disease or at the time of relapse for patients receiving transplants at relapse. All biopsy specimens were reviewed and confirmed by an expert hematopathologist at City of Hope. Written informed consent was obtained from each patient and the study was approved by the City of Hope Institutional Review Board.
Study DeJinitions and Evaluation
Patients were defined as having induction failure if they had received an induction chemotherapy with or without salvage therapy and were never documented to be in a CR. A sensitive relapse was defined as at least a 50% reduction in the bidimensional measurements of the disease with the use of conventional salvage chemotherapy or radiotherapy. A resistant relapse was defined as less than 50% reduction in the size of the tumor with the use of conventional salvage chemotherapy.
Patients were clinically restaged at the time of entry onto the study. Restaging procedures were repeated at day +30, +l00 after BMT, or as clinically indicated. Follow-up tumor restaging was performed every 3 to 6 months for 2 years, then yearly unless recurrent disease was suspected. Patients who survived to at least day +30 and had no evidence of tumor by clinical and radiologic evaluation for at least one month were classified as having a CR. Patients with small residual radiographic abnormalities that did not progress for 6 months after transplant were classified as having attained CR. Patients who were received transplants in CR without evidence of disease were considered to be in continuous CR (CCR) after transplant. Partial remission (PR) was defined as a reduction of 50% or more of measurable disease for at least 1 month.
Patient Selection
Patients were eligible for ABMT if they had failed to achieve CR after first-line chemotherapy or chemoradiotherapy (induction failure), or if they had relapsed after standard chemotherapy regimens for HD. In this study, patients whose first relapse occurred more than 12 months after completion of induction chemotherapy were not candidates for ABMT unless they had failed to respond to standard salvage chemotherapy or had a relapse at extranodal sites. Additional eligibility criteria included: age <60 years, Karnofsky performance status (KPS) 270, left ventricular ejection fraction >50%, forced expiratory volume in 1 second (FEV,) or diffusion capacity of the lung for carbon monoxide (DLCO) >50% predicted, and no major organ dysfunction unrelated to their underlying HD. Patients were eligible for autologous peripheral blood stem cell (PBSC) transplantation if they had histologic evidence of bone marrow (BM) involvement at any time during the course of their disease, a marrow cellularity of less than 30% with a prior history of pelvic irradiation, or evidence of widespread metastatic bone disease by isotope bone scan or magnetic resonance imaging (MRI). 
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The patient characteristics are shown in Table 1 . The median age was 32 years (range, 16 to 56). There were 41 men and 44 women. The majority of the patients (69%) had stage 111 or IV disease and 44 patients (52%) had "B" symptoms at diagnosis. Twenty-seven patients (32%) had extranodal involvement at diagnosis. Details of prior therapy are outlined in Table 2 . All patients had received combination chemotherapy as initial treatment or as salvage therapy. The median number of prior chemotherapy regimens was 3 (range, I to 7). Sixty-five patients (76%) had received prior radiation therapy, either at initial presentation or as salvage therapy for previous relapse, including mantle field radiation in 48 patients (56%).
The patient characteristics at ABMT are shown in Table 3 . Fortythree (51%) patients received transplants in first relapse or second CR and 33 (39%) received transplants after second or subsequent relapse. The median duration of first CR to first relapse was 1 1 months (range, 1 to 97) and 39 patients (51%) relapsed within 12 months from initial CR. Among the relapsed patients, 65 (86%) of them had sensitive relapse. The median KPS at BMT was 90% (range, 80 to 100). Twenty-one patients (25%) had extranodal disease at the time of transplant.
Reinduction Therapy
Conventional salvage chemotherapy or radiotherapy was given to all relapsed patients, except one, to reduce the bulk of disease and to test for chemosensitivity. One patient with minimal disease received transplant in early relapse without reinduction therapy. The list of For personal use only. on October 3, 2017. by guest www.bloodjournal.org From Patients may require more than one form of therapy.
salvage chemotherapies is shown in Table 2 . Most patients received two to three cycles of salvage therapy to achieve maximal response before ABMT. The choices of salvage chemotherapy were dependent on the initial induction chemotherapy and the duration of first CR. Patients who relapsed following initial therapy with mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) received doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) and those who relapsed following ABVD received MOPP as salvage therapy. Patients who relapsed following seven-or eight-drug combinations (MOPP alternating with ABVD or MOPP/ABV hybrid regimen) received yet another combination therapy, ie, etoposide, steroid, cytarabine, and cisplatin (ESAP)," dexamethasone, high-dose cytarabine, and cisplatin (DHAP)?' or other salvage regimens. Those who relapsed more than 12 months after initial CR usually received reinduction therapy using the same regimen that achieved the initial CR; and only those patients who failed to attain a second remission or had a relapse at extranodal sites were candidates for ABMT. Patients with bulky disease ( 2 5 cm) or those with disease confined to nodal areas, which could be encompassed within a previously untreated radiotherapy site, received salvage radiotherapy 3,000 to 3,500 Gy ( Table 2 ) before ABMT. Patients were not excluded from ABMT if they failed to respond to salvage reinduction chemotherapy or radiotherapy unless they had rapidly progressive disease with extranodal involvement limiting their performance status.
Preparative Regimen
As described earlier, there were two preparatory regimens used in this study. Twenty-two (26%) patients received a preparative regimen consisting of FI'BI 1,200 cGy at 120 cGy per fraction X 10 fractions or 200 cGy X 6 fractions, delivered from day -8 through day -5 in combination with etoposide (60 mglkg) intravenously (IV) over 4 hours on day -4 and cyclophosphamide (100 mglkg, ideal body weight) IV over 2 hours on day -2. During FI'BI, the lungs were shielded with 50% transmission blocks for all fractions. Sixty-three (74%) patients with prior radiation therapy received highdose BCNU instead of FTBI. Initially BCNU either 450 mg/m2 or 15 mgkg was administered IV over 4 hours on day -6; subsequently, BCNU was changed to 150 mg/mz IV over 2 hours daily on days -6, -5, and -4. Involved field radiotherapy boost of 2,000 Gy to residual bulky masses 2 5 cm delivered over 2 weeks before BMT was also given in 17 patients.
Autologous Marrow Harvest, Cryopreservation, PBSC Collection, and Reinfusion
All patients had undergone bilateral iliac crest BM aspiration and biopsies, showing no microscopic evidence of involvement by HD at the time of BM harvesting. In addition, cytogenetic studies were also performed and were normal in all patients, and those patients with cytogenetic abnormalities were excluded. The technique o f BM harvest has been previously described? ' Patients with prior BM/bone involvement or with a hypocellular marrow underwent PBSC collections via leukapheresis procedures as previously described. After collection, the BM and PBSC were suspended in 5% dimethylsulfoxide (DMSO) and 6% hydroxyethyl starch (HES) and were cryopreserved without rate-controlled freezing by simple immersion in a -130°C freezer until needed.24 On day 0, the cryopreserved BM and/or PBSC were removed from the freezer, transported to the patient's bedside, thawed in a 37°C water For personal use only. on October 3, 2017. by guest www.bloodjournal.org From bath, and immediately infused through a central venous catheter without filtration over 5 to 10 minutes.
Between 1988 and 1991, patients without marrow involvement who had BM nucleated cell yields 52.0 X 108kg also underwent three PBSC collections during the steady state without priming with chemotherapy or growth factor, and were transplanted with a combination of BM and PBSCs. Since 1991, PBSC were collected after priming with recombinant granulocyte colony-stimulating factor (G-CSF) at a dose of 5 or 10 pgkgld administered subcutaneously or IV daily until the PBSC collection was completed. PBSC collection was begun on day 5 and continued daily until a target dose of 10 X lo8 mononuclear cellskg were collected in patients receiving only PBSC. For patients receiving combined BM and primed PBSC, only three PBSC collections were done after priming with G-CSF S pg/ Twenty-five patients (29%) received BM only, 38 (45%) received BM and PBSC, and 22 (26%) received PBSC only. The median number of marrow nucleated cell infused was 2.2 X 108kg (range, 0.2 to 8.0). The median number of mononuclear cells given were 10.7 X 1Oxkg (range, 5.9 to 25.0) for patients receiving PBSC only, and 4.2 X 108kg (range, 0.9 to 13.8) for those receiving combined BM and PBSCs. kg.
Supportive Care
All patients were housed in private rooms with high-efficiency particulate air filtration systems. Nonabsorbable antibiotics were used; however prophylactic antibiotics were not given. Broad spectrum antibiotics were started for the first febrile episode. Trimethoprim-sulfamethoxazole was administered from day -13 or -9 to day -3; prophylaxis was reinstituted at the time of discharge or when the leukocyte count >2 X 109/L, and continued until 6 months posttransplant. All patients received prophylactic low-dose amphotericin (0.15 mgkg) starting on day + l and continuing daily until di~charge.'~ Total parenteral nutrition was given to all patients until they were able to eat. All blood products were irradiated with 2,500 Gy. Platelets were transfused to maintain a platelet count above 20 X I O Y L Since 1991, G-CSF 5 pgkg/d IV was also administered beginning on day + I and continuing daily until absolute granulocyte count was > O S X 109/L on 3 consecutive days.
Statistical Analysis
Demographic and disease characteristics were summarized for all patients using descriptive statistics. Survival estimates were calculated based on the product-limit method, and 95% confidence intervals were calculated using the logit transformation with Greenwood's variance estimate. Factors possibly associated with OS, DFS, and relapse were examined by univariate Cox regression analysis. The assumption of proportionality of the hazard ratio was first tested for each variable. The variables tested included age, sex, stage at diagnosis, "B" symptom at diagnosis and at ABMT, extranodal disease at diagnosis and at ABMT, BM involvement, performance status, number of prior chemotherapy regimens, prior radiation therapy, status at ABMT, length of first CR (< 12 months v 2 12 months), type of relapse (sensitive v resistant), conditioning regimen, hematopoietic rescue source, and use of hematopoietic growth factor post-ABMT. Because of small sample size and no statistical difference in the outcome between patients transplanted in first relapse (1 REL) or second CR (2CR), the analysis was performed in three groups of patients based on status at ABMT: induction failure (IF), lREL/ 2CR, and advanced group (>lREL and >2CR).
The risk ratio was calculated for each significant variable, along with the 95% confidence limits. Stepwise Cox regression was then performed to determine independent predictors of survival and relapse; all variables with a P value <.l0 on univariate analysis were included as candidates in this analysis. The multivariate analysis was also performed adjusting for status at transplant (1RL/2CR v beyond 1RL/2CR), by forcing this variable into the equation before testing for the significance of the other factors.
RESULTS
Therapeutic Results
Currently 57 patients (67%) are alive, including 44 in continuous CR with a median follow-up for the surviving patients of 28 months (range, 7 to 66). Twenty-eight patients (33%) have died, 17 due to progressive HD and 11 due to transplant-related complications. The cumulative probability of survival for all 85 patients is 76% (95% CI, 6 4 % to 84%) with a median follow-up of 25 months (range, 0.6 to 66) (Fig 1) . The cumulative probability of DFS of all 85 patients at 2 year was 58% (95% CI, 47% to 69%) and is also shown in Fig 1. 
Antitumor Response
There were five early deaths not evaluable for response. At 30 days, 61 patients (76%), including 37 patients receiving transplants in CR, were in complete remission. Five additional patients (6%) achieved PR. Twelve patients (15%) had stable disease and two patients (3%) did not respond. Without additional therapy, a restaging was performed at 3 months, 68 patients (87%) were in CR, one patient (1%) in PR, four patients (5%) with stable disease, and five other patients (7%) progressed.
Comparison Between FTBI Versus Non-FTBI Regimen
The patient characteristics and outcome between the two treatment arms are shown in Table 4 . There was no significant difference in status at transplant or number of prior chemotherapy regimens between the two groups, except that all patients receiving mBI-containing regimen had relapsed after chemotherapy only, whereas patients receiving BCNU were heterogeneous and included patients who had relapsed following combined modality treatment. There was no sigFor personal use only. on October 3, 2017. by guest www.bloodjournal.org From nificant difference in the rate of hematopoietic recovery, length of hospital stay, response rate, OS, and DFS between the two groups. Five patients (8%) in the BCNU group developed pulmonary toxicity or interstitial pneumonitis (IP), two of which were fatal compared with two (9%) in the FTBI group, which included one late fatal IP and one pulmonary hemorrhage, that resolved after high-dose corticosteroid. All patients who developed IP in the BCNU group had received mediastinal radiation.
Relapse
Thirty patients (35%) developed progressive disease after transplant including the two patients who did not have an initial antitumor response after ABMT. The median time from ABMT to relapse was 9 months (range, 1 to 43). The probability of disease progression at 2 years was 34% (95% CI, 23% to 46%). Twenty-three patients suffered relapses in sites of previous disease; whereas seven patients developed disease in new sites, including one with BM involvement. Relapses were nodal only in 17 patients, and 13 patients relapsed at extranodal sites with or without concomitant 1385 nodal disease. Six patients had late relapse between 24 and 43 months post-ABMT. Based on Cox regression analysis, the number of prior chemotherapy regimens was the only prognostic variable significantly associated with increased risk of relapse (P = .01).
Prognostic Factors for Survival
Results of univariate and stepwise Cox regression analyses of prognostic factors for DFS and OS are shown in Table  5 . By univariate analysis, only the number of prior chemotherapy regimens was significantly related to DFS (P = .006), whereas prior radiation therapy and presence of extranodal disease at transplant were of borderline statistical significance and associated with poorer DFS (P = .07 and .08, respectively). Stepwise Cox regression identified the number of chemotherapy regimens as the only factor that significantly influenced DFS ( P = .008), and it remained significant (P = .01) when adjusting for status at transplant. The DFS curve, stratified by the number of prior chemotherapy regimens is shown in Fig 2. In this analysis, the length of initial CR was not significant. The cumulative probability of DFS at 2 years was 63% (95% CI, 46% to 77%) for the group with initial CR 2 1 2 months, compared with 51% (95% CI, 35% to 67%) for the group with short initial CR < 12 months ( P = .58). In addition, we found that the status at transplant was not a significant factor influencing the DFS (P = .47); the DFS curve based on status at ABMT is shown in Fig 3 .
In univariate analysis, three independent variables were also found to be significantly associated with a reduced OS: number of prior chemotherapy regimens (P = .001), prior radiotherapy (P = .OS), and presence of extranodal disease at transplant ( P = .01). However, only the number of prior chemotherapy regimens ( P = .003) and the presence of extranodal disease at transplant (P = .02) remained significant in the stepwise Cox regression model.
Toxicity
Engraftment. Two patients who died before day +30 were not evaluated for hematologic recovery. An additional three patients died after granulocyte recovery but before platelet recovery. One patient died of graft failure and one patient had delayed engraftment, but remains alive with pancytopenia. In the 82 evaluable patients, the median day to reach an absolute neutrophil count (ANC) 20.5 X 109L was 13.5 (range, 10 to 42), 13 (range, 10 to 50), and 13 days (range, 8 to 65) for patients receiving BM only, PBSC only, and combined BM and PBSC, respectively. Two patients never had platelet counts below 20 X lo9& one patient had persistent thrombocytopenia, and documentation of platelet recovery was missing in one patient. In the 76 patients evaluable for platelet recovery, the median days to achieve a platelet count 2 2 0 X 109L without platelet transfusion was 21 days (range, 7 to 54), 18 days (range, 7 to 305), and 18 days (range, 0 to 96) for those receiving BM only, PBSC only, and combined BM and PBSC, respectively. There was no significant difference in the rate of granulocyte (P = .98) and platelet (P = .83) recovery among the patients receiving autologous BM only, PBSC only, and combined BM and PBSC.
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Nonrelapse Mortality
Eleven patients (l 3%) died of transplant-related complications. There were 7 early deaths within 100 days posttransplant, including fatal venoocclusive disease of the liver (VOD) in 5 patients, BCNU-induced IP in 1 patient, and cerebral hemorrhage in 1 patient. One patient died of graft failure and infection at 5 months post-ABMT. Two patients died of late IP and pulmonary fibrosis at 17 and 46 months after transplant. The remaining patient developed therapy induced myelodysplasia (MDS)/acute leukemia at 2.4 years posttransplant, and then underwent allogeneic BMT from a histocompatible sibling donor, and subsequently died of progressive leukemia. The estimated probability of death from transplant-related complications at 2 years was 11% (95% CI, 6% to 20%).
Second Malignancies
Three patients developed therapy-induced MDS at 9, 10, and 29 months post-ABMT. The time from diagnosis of HD to the development of MDS ranged between 2.0 to 4.2 years. Two patients had received two prior chemotherapy regimens and one had received three; two also had received radiation therapy. Diagnosis of MDS was made at the time of relapse in two patients, while the other patient described above was diagnosed during remission. One patient died of progressive HD and acute leukemia at 15 months after diagnosis of acute leukemia, one patient is still alive with active HD and MDS, and the third patient died of progressive leukemia following allogeneic BMT. The estimated probability of developing therapy-induced MDS/acute leukemia was 3% (95% CI, 0.7% to 11%) and 6% (95% CI, 2% to 17%) at 2 and 3 years, respectively.
DISCUSSION
Our results show that high-dose chemotherapy or chemo/ radiotherapy followed by ABMT can induce long-term disease control and improve the prognosis of the patients with advanced refractory or relapsed HD. Our patient population in this study was heterogeneous and heavily pretreated, with a median of three chemotherapy regimens before ABMT. In addition, 76% of the patients had received prior radiotherapy. Despite this, 52% of the patients are alive and disease-free at a median follow-up of 25 months.
Our BCNUNP-16ICTX combination is well tolerated. The response rates and overall results compare favorably with other high-dose combination chemotherapy with four For personal use only. on October 3, 2017. by guest www.bloodjournal.org From drugs regimen BEAM,I3 or three drugs CBV which included heavily pretreated patiehts similar to our patient population. When o$ BCNUNP-16ICTX is compared with the augmented CEiV regimen ieported by Reece et a18 (which used a higher dose of BCNU at 600 mg/m2), both the incidences of toxic death h d BCNU associated IP were lower in our study. Pulmonary toxicity has been observed more frequently in patients.receiving 600 mg/m' of BCNU27 and in those patients with prior mediastinal irradiation, especially within 3 months ljefore 'IABMT.'~ Despite the lower incidence of IP in our $udy, tko patients in our study died of BCNU associated puponary toxicity including acute BCNU IP and late interstitial4ibrosis. Early recognition and immediate treatment with corjicostero!ds have been reported to prevent the fatal In addition, a divided dosing schedule may reduce the acute side effects and the incidence of BCNU IP."
The experience with TBI-condning regimens and ABMT in HD has been limited to a few studies with.smal1 numbers of patients in each s t~d y . '~* '~.~~
The earlier results were associated with a high incidence of bansplant-related mortality due to patient selection and the'inclusion of patients with prior mediastinal radiation in ;these studies. In a study of ABMT in HD using the combifiation of TB1 and cyclophosphamide reported by Phillips e t al, the CR rate was 69% but the early toxic death rate was 23%, which was higher than in most other reports." Several studies have also confirmed that the incidence of IP was hgher in patients with prior mediastinal radiation who received TBI-containing regimens." Recently, Yahalom et a1 incorporated hyperfractionated total-lymphoid irradiation into the combination with high-dose etoposide and cyclophosphamide followed by ABMT in 47 patients with relapsed or chemo-resistant HD who had not received prior radiation therapy.I5 The CR rate was 74% and the actuarial DFS at 6.5 year was 50%. However, a relatively high (17%) treatment-related death rate was observed, mostly due to respiratory failure secondary to diffuse alveolar hemorrhage. Our Q B W P -16/CTX regimen was well tolerated and was associated with less transplantrelated toxicity. Only two patients deveibped pulmonary complications from diffuse alveolai' hemorrhage and late interstitial fibrosis. Although our Sample size is relatively small, overall results appear superior to previous reports of TBI-containing regimen. This suggests that $e combination of etoposide, TBI, and cyclophosphamide aldng with patient selection (no prior radiotherapy) m d supportive care may contribute to the improved outcome in, this study.
We found no differences in t&e re!ponsq rate, survival, DFS, and toxicity between the two rkgimens used in this study. However, the patient groups may not have been comparable, as the assignment to the preparative regimen was based on the patient's history of prior treatnient with radiotherapy. Prospective trials with a larger number of patients and a longer follow-up will be required to determine if significant differences exist between the two regimens. However, it is relevant to note that, regardless of the outcome, a non-TB1 containing regimen may be preferable because of its feasibility, especially in patients With prior radiotherapy.
A number of prognostic factors that predict for the outcome of ABMT in HD have been identified in several studies including performance status at BMT, number of prior chemotherapies regimens, disease status at BMT, sensitivity to salvage therapy, duration of first CR, and tumor bulk at the prior chemotherapy regimens was the only prognostic factor that was associated with both relapse and survival. Patients who had received more than two chemotherapy regimens had a poorer DFS and were at increased risk of relapse and death from transplant-related complications. Our results would favor early transplantation before developing drug resistance and cumulative organ toxicity from cytotoxic agents to decrease the risk of relapse and reduce the transplant-related morbidity.
In contrast to the report of Reece et al," the duration of first CR had no influence on the outcome of ABMT in our study; this is true even in those patients who received transplants while in first relapse and in second CR. The difference in outcome may, in part, be a result of patient selection. In our study, patients in first relapse after initial CR > l 2 months were transplanted only if they had failed to respond to salvage therapy thus selecting patients with more refractory disease.
The optimal timing of ABMT in HD remains debatable. High-dose therapy and ABMT is clearly indicated in patients who fail to achieve an initial remission with combination chemotherapy or have primary refractory disease. The prognosis for these patients is extremely poor with conventional salvage therapy and no long-term survival can be expected. Although based on a small number of patients, the 67% 2-year DFS in our six patients with induction failure confirm the previous r e s~l t s ,~~~'~~~~~~ and suggest that high-dose therapy and ABMT is the treatment of choice for these patients.
Likewise, patients who relapse within 12 months of attaining first CR do poorly with salvage chemotherapy or radiotherapy, and high-dose therapy with ABMT have also been shown to improve survival in this g r o~p .~' ,~~.~~ Although, the follow-up time in our study is relatively short, we observed 51% DFS at two years in these patients, which is clearly superior to the results obtained with conventional salvage regimen^.^ The role of ABMT in patients with first relapse after initial chemotherapy induced CR of longer than 12 months remains controversial. Many investigators would not recommend transplanting these patients if they can achieve second remission with Conventional salvage therapy.3o Seventeen patients in our study whose initial CR length 2 12 months, received transplants in first relapse or second CR. The 2-year DFS in this group was 76% (95% CI, 51% to 91%), which is comparable to the results reported by Reece et a l l 7 in 58 patients with relapsed HD who received transplants in first relapse after initial therapy with seven-or eight-drug combination chemotherapy. Even though patient selection may be a factor, these results are clearly superior to the results reported with conventional salvage chemotherapy regimens, and provide a strong argument for high-dose therapy and ABMT after first relapse, even in patients with a chemotherapy induced first CR of > 12 months.
For patients who were transplanted in second or subsetime of ~splant.13,14.16.17.26.. 29 In our study, the number of For personal use only. on October 3, 2017. by guest www.bloodjournal.org From quent relapse, only 20% to 30% of these patients became long-term disease-free survivors. In addition, these patients were more likely to experience transplant-related mortality due to end organ damage from extensive prior therapy. These results would also argue for early transplantation. Development of more effective regimens and newer approaches for reducing transplant-related morbidity and mortality may improve the outcome of ABMT in these patients.
Late relapse has been well described in patients with HD, especially with nodular sclerosis histology."." This observation has now been reported in patients with HD after highdose therapy and ABMT in several series.8.'3.'R.2h Six patients in our study experienced late relapse between 24 and 43 months after transplant. Four of these patients had nodular sclerosis, and all patients were transplanted in second or subsequent CR or relapse. Three patients remain alive after salvage therapy suggesting that these patients may have different disease biology. Therefore, it is very important to recognize that these patients are still at risk for relapse, and long-term follow-up is necessary to determine the overall curability obtained with transplantation.
Despite the success of ABMT in HD, the transplant-related mortality continues to be a major concern. The 13% transplant-related mortality in our study is comparable to previously reported experiences of ABMT in HD. The introduction of hematopoietic growth factor and the addition of mobilized PBSC into the transplant armamentarium have clearly reduced septic complication; however, nonhematologic toxicities remain problematic. Pulmonary toxicity is one of the major causes of death in several series, especially those using higher doses of BCNU,8.28 patients with prior mediastinal irradiation are particularly at risk. Careful monitoring of pulmonary symptoms and early treatment with corticosteroid may prevent pulmonary death in some patients; however, delayed pulmonary fibrosis may still occur. Two patients in our study died of late onset interstitial fibrosis at 17 and 46 months posttransplant. One of these patients had received both BCNU and mediastinal radiation. Both patients had insidious onset of dysnea. The chest radiographs showed diffuse interstitial infiltrates and pulmonary function studies showed severe restrictive lung disease. Bronchoalveolar lavage showed no organism. BCNU associated pulmonary toxicity was the most likely diagnosis in one patient and TB1 or cyclophosphamide toxicity in the other. Five patients in our study also died of VOD, a well-known complication of transplant associated with extensive prior therapy, prior abdominal radiation, and antecedent liver disease.33 Perhaps this complication can be ameliorated by early transplantation.
Recently, therapy-induced MDS and acute leukemia have been reported after ABMT for both HD and non-Hodgkin's lymphoma in a few s t~d i e s , " ,~' .~~ which is of major concern. The majority of our patients had cytogenetic studies done before marrow or stem cell harvest and were normal. Potential ABMT candidates with abnormal cytogenetic studies were excluded from ABMT.'s This complication occurred in both treatment groups, and we found that the type of conditioning regimen was not a risk factor for developing MDS.34 Stem cell injuries from prior exposure to alkylating agents is probably the most likely cause of MDS in these patients. This observation would suggest that early transplantation should be done to avoid exposure of autologous bone marrow or hematopoietic stem cell to repeated cycles of salvage therapy.
Is there an alternative treatment to high-dose therapy and ABMT in patients with relapsed HD? Few studies have used several courses of intensive high-dose chemotherapy without factors have been shown to abrogate myelotoxicity from repetitive cycles of high-dose combination chemotherapy in patients with solid t~m o r s .~' .~~ This approach of repetitive high-dose combination chemotherapy with growth factor and mobilized PBSC rescue after each course may potentially improve the therapeutic index and reduce the toxicities of high-dose chemotherapy. New therapeutic strategy such as posttransplant immunotherapy should also be explored.
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